tradingkey.logo


Bausch Health Companies Inc

BHC

5.715USD

+0.005+0.09%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
2.11BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Bausch Health Companies Inc āļšāļĢāļīāļĐāļąāļ—
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BHC
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Bausch Health Companies Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 1994
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Thomas J. Appio
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™20700
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Sep 20
āļ—āļĩāđˆāļ­āļĒāļđāđˆ2150 St. Elzear Blvd. West
āđ€āļĄāļ·āļ­āļ‡LAVAL
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒThe Toronto Stock Exchange
āļ›āļĢāļ°āđ€āļ—āļĻCanada
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒH7L 4A8
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18003611448
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.bauschhealth.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BHC
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 1994
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Thomas J. Appio
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
627.22K
-24.81%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
264.39K
+0.39%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
254.72K
+27.12%
Mr. Steven D. Miller
Mr. Steven D. Miller
Independent Director
Independent Director
239.22K
+29.40%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
225.40K
+1.82%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
30.15K
--
Mr. Michael Goettler
Mr. Michael Goettler
Director
Director
30.15K
--
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
8.11K
--
Dr. Richard C. Mulligan, Ph.D.
Dr. Richard C. Mulligan, Ph.D.
Independent Director
Independent Director
--
--
Mr. John A. Paulson
Mr. John A. Paulson
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
627.22K
-24.81%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
264.39K
+0.39%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
254.72K
+27.12%
Mr. Steven D. Miller
Mr. Steven D. Miller
Independent Director
Independent Director
239.22K
+29.40%
Mr. Brett M. Icahn
Mr. Brett M. Icahn
Independent Director
Independent Director
225.40K
+1.82%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
30.15K
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States and Puerto Rico
5.77B
59.92%
Other Foreign Countries
1.08B
11.25%
China (Country)
496.00M
5.15%
Canada
402.00M
4.18%
Poland
350.00M
3.64%
Other
1.53B
15.86%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Meruelo (Alex)
9.94%
Icahn Associates Corporation
9.39%
Paulson & Co. Inc.
8.87%
GoldenTree Asset Management, LP
8.18%
Nomura Securities Co., Ltd.
6.33%
Other
57.29%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Meruelo (Alex)
9.94%
Icahn Associates Corporation
9.39%
Paulson & Co. Inc.
8.87%
GoldenTree Asset Management, LP
8.18%
Nomura Securities Co., Ltd.
6.33%
Other
57.29%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
16.30%
Individual Investor
11.04%
Family Office
8.87%
Research Firm
8.65%
Investment Advisor
8.64%
Bank and Trust
4.41%
Pension Fund
4.26%
Private Equity
1.42%
Other
19.98%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
514
263.21M
71.22%
-46.16M
2025Q1
547
263.71M
71.37%
-49.89M
2024Q4
568
275.73M
74.96%
-32.06M
2024Q3
627
279.89M
77.25%
-44.78M
2024Q2
703
283.62M
78.54%
-59.67M
2024Q1
764
278.87M
76.11%
-93.72M
2023Q4
801
283.62M
78.55%
-85.16M
2023Q3
821
301.23M
82.72%
-52.06M
2023Q2
836
283.61M
80.53%
-76.52M
2023Q1
862
290.05M
79.80%
-77.57M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Meruelo (Alex)
36.76M
9.95%
+148.73K
+0.41%
Mar 31, 2025
Icahn Associates Corporation
34.72M
9.4%
--
--
May 20, 2025
Paulson & Co. Inc.
32.79M
8.87%
+6.35M
+24.03%
Jun 13, 2025
GoldenTree Asset Management, LP
30.25M
8.19%
+2.71M
+9.84%
Mar 31, 2025
Nomura Securities Co., Ltd.
23.39M
6.33%
+12.05M
+106.21%
Mar 31, 2025
Healthcare Of Ontario Pension Plan
13.00M
3.52%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.68M
3.16%
+61.62K
+0.53%
Mar 31, 2025
National Bank of Canada
7.51M
2.03%
-7.91M
-51.29%
Mar 31, 2025
Maple Rock Capital Partners, Inc.
6.80M
1.84%
+1.50M
+28.25%
Mar 31, 2025
Macquarie Investment Management Global Ltd.
6.60M
1.79%
--
--
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Gotham 1000 Value ETF
0.18%
VanEck Pharmaceutical ETF
0.14%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
0.12%
JPMorgan International Value ETF
0.09%
Schwab International Small-Cap Equity ETF
0.08%
iShares Intl Small Cap Equity Factor ETF
0.06%
DFA Dimensional International Small Cap ETF
0.05%
Schwab Fundamental International Equity ETF
0.04%
Invesco RAFI Developed Mkts ex-US ETF
0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
0.01%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Gotham 1000 Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.18%
VanEck Pharmaceutical ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.14%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%
JPMorgan International Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.09%
Schwab International Small-Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.08%
iShares Intl Small Cap Equity Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.06%
DFA Dimensional International Small Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.05%
Schwab Fundamental International Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.04%
Invesco RAFI Developed Mkts ex-US ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™